Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Month Year
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Jun 20, 2003Insmed Receives European Orphan Drug Designation For rhIGF-I/rhIGFBP-3; Product Will Have 10 Years of Market Exclusivity in Treatment of Growth Disorder
-
Jun 19, 2003Insmed Announces Management Reorganization; Ronald D. Gunn Promoted to Executive VP; Lewis Stuart Departs as VP Commercial Development
-
Jun 18, 2003Insmed to Present Lead Drug Candidate at the Endocrine Society Annual Meeting
-
Jun 17, 2003Insmed Selected to Present to BIO 2003 Business Forum; Presentation to be Webcast Live
-
Jun 12, 2003Insmed to Report Positive Effects of rhIGF-I/rhIGFBP-3 In Adolescent Subjects with Type 1 Diabetes
-
Jun 2, 2003Insmed Presents Data To ASCO Highlighting Potential Benefit Of rhIGFBP-3 in Cancer; rhIGFBP-3 Shown to Enhance Chemotherapy in Models of Human Breast Cancer
-
May 29, 2003Insmed to Present Positive Cancer Data to ASCO
-
May 16, 2003Insmed Incorporated to Present at Techvest European Healthcare Conference
-
May 12, 2003Insmed Regains Full Compliance with Nasdaq National Market System Listing Requirements
-
May 2, 2003Insmed Incorporated Announces Improved Financial Results for First Quarter 2003; Narrowing of Net Loss Exceeds Expectations; Cash Burn Rate Drops Sharply
-
Apr 25, 2003Insmed Incorporated To Webcast First Quarter Earnings Conference Call; Friday, May 2, at 11:00 a.m. ET - 10:00 a.m. CT
-
Apr 11, 2003Insmed Announces Publication of Investment Profile; Full Text Available on Corporate Website
-
Apr 8, 2003Insmed Chairman to Provide Positive Outlook During CEOcast.com's Virtual Healthcare Conference
-
Apr 8, 2003Insmed Initiates Named Patient Programme For rhIGF-I/rhIGFBP-3, An Investigational Drug for Severe Growth Disorders
-
Apr 7, 2003Insmed Announces Improved Performance Expectations for First Quarter; Lead Product Candidate Prepared to Enter Phase III Trials
-
Apr 4, 2003Insmed Reports Positive Data with rhIGFBP-3 in Cancer; rhIGFBP-3 Improves Effect of Standard Cancer Therapies; rhIGFBP-3 Inhibits Tumor Growth up to 70%
-
Apr 2, 2003Insmed CEO to Highlight Near Term Commercial Opportunity; Lead Drug on Track for Potential FDA Approval in 2004; Cash Expected to Fund Operations Through Potential Approval
-
Apr 1, 2003Insmed Chairman And CEO Provides Positive Outlook in Special Letter to Shareholders
-
Mar 28, 2003Insmed Incorporated Retains Investor Relations International As Investor Relations Counsel; Company to Immediately Implement New Shareholder Communications Program
-
Feb 3, 2003Insmed Incorporated Reports Year-End and Fourth Quarter Financial Results
-
Jan 29, 2003Insmed Reports Positive Effects of SomatoKine -rhIGF-I/rhIGFBP-3- In Adolescent Subjects With Type 1 Diabetes
-
Jan 28, 2003Insmed Incorporated to Webcast Fourth Quarter Earnings Conference Call; Tuesday, February 4, at 8:00 a.m. ET - 7:00 a.m. CT
-
Jan 27, 2003Insmed Incorporated Appeals Delisting Notification From Nasdaq
-
Jan 7, 2003Insmed Incorporated Announces Positive Preclinical Oncology Data With rhIGFBP-3
-
Nov 4, 2002Insmed Presents IGFBP-3 Anti-Cancer Data at the International Symposium on the Functional Role of IGFBP's
-
Oct 31, 2002Insmed Incorporated To Webcast Third Quarter Earnings Conference Call; Thursday, October 31, 2002, at 8:30 a.m. ET -7:30 a.m. CT
-
Oct 30, 2002Insmed Incorporated Reports Third Quarter Results
-
Oct 7, 2002Insmed Acquires IGF-1 Regulatory Files for Growth Hormone Insensitivity Syndrome From Pharmacia; Extensive Regulatory Files Expected to Expedite Commercialization of SomatoKine
-
Sep 23, 2002Insmed Restructures to Advance Most Promising Drug Candidates and Optimize Resources
-
Sep 10, 2002Insmed Discontinues Internal Development of INS-1 for Diabetes and Polycystic Ovary Syndrome - PCOS -
-
Sep 9, 2002Insmed Announces Appointment of Mary Callan as Vice President of Corporate Development
-
Aug 19, 2002Insmed Announces Appointment of Vice President of Commercial Development
-
Jul 29, 2002Insmed Incorporated and Avecia Limited Announce Development and Manufacturing Agreement for SomatoKine
-
Jul 26, 2002Insmed Incorporated Reports Second Quarter Results
-
Jul 25, 2002Insmed Incorporated Invites You to Join Its 2nd Quarter Earnings Conference Call On: Tuesday, July 30, 2002 at 9:00 a.m. EDT
-
Jul 18, 2002Insmed Presents Lead Drug Candidates At ENDO 2002, The 84th Annual Meeting of the Endocrine Society
-
Jul 17, 2002Insmed Incorporated Receives Orphan Drug Designation for SomatoKine for the Treatment of Growth Hormone Insensitivity Syndrome -Laron Syndrome- and Inititates Clinical Study
-
Jul 8, 2002Insmed Incorporated Announces Investor Update Conference Call; Tuesday, July 9, 2002, at 9:00 a.m. ET - 8:00 a.m. CT
-
Jun 17, 2002Insmed Reports Data On Insulin Sensitizing Drug At American Diabetes Associations Annual Meeting
-
Jun 13, 2002Insmed Announces That Data At American Diabetes Association Annual Meeting Will Highlight Drug Pipeline
-
May 2, 2002Insmed Incorporated Reports First Quarter Results
-
Apr 26, 2002Insmed Incorporated to Webcast First Quarter Investor Update Conference Call; Friday, May 03, 2002, at 8:00 a.m. ET
-
Feb 18, 2002Insmed Incorporated and Oxagen Limited Form Partnership to Create a Genetic Study of Polycystic Ovary Syndrome
-
Feb 8, 2002Insmed Incorporated to Present at Wall Street Analyst Forum
-
Jan 30, 2002Insmed Incorporated Reports Fourth Quarter and Year-end Financial Results
-
Jan 24, 2002Insmed Incorporated to Webcast Fourth Quarter Investor Update Conference Call; Thursday, January 31, 2002, at 8:00 a.m. ET -7 a.m. CT
-
Jan 8, 2002Insmed Reports Positive Effects of SomatoKine in Subjects With Type 2 Diabetes
-
Jan 3, 2002Insmed Appoints Vice President of Clinical Development
